Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.
Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C. Ingenhoven K, et al. Among authors: creeke p. Front Neurol. 2017 Jul 6;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017. Front Neurol. 2017. PMID: 28729851 Free PMC article.
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A; ABIRISK Consortium. Hermanrud C, et al. Among authors: creeke p. J Immunol Methods. 2016 Mar;430:1-9. doi: 10.1016/j.jim.2016.01.004. Epub 2016 Jan 11. J Immunol Methods. 2016. PMID: 26779831
Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.
Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, Sievers C, Lindberg Gasser RL, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnes P, Mauri C, Jury EC; ABIRISK Consortium. Adriani M, et al. Among authors: creeke p. JCI Insight. 2018 Jun 7;3(11):e99274. doi: 10.1172/jci.insight.99274. eCollection 2018 Jun 7. JCI Insight. 2018. PMID: 29875313 Free PMC article.
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.
Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium. Rup B, et al. Among authors: creeke p. Clin Exp Immunol. 2015 Sep;181(3):385-400. doi: 10.1111/cei.12652. Epub 2015 Jul 2. Clin Exp Immunol. 2015. PMID: 25959571 Free PMC article. Review.
Development of resistance to biologic therapies with reference to IFN-β.
Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI. Farrell RA, et al. Among authors: creeke pi. Rheumatology (Oxford). 2012 Apr;51(4):590-9. doi: 10.1093/rheumatology/ker445. Epub 2012 Jan 18. Rheumatology (Oxford). 2012. PMID: 22258390 Review.
18 results